{
  "id": "b8c6f558-9cbd-4389-a8d7-a8c698c49093",
  "code": {
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL"
  },
  "name": "Tyrvaya",
  "organization": "Oyster Point Pharma, Inc.",
  "effectiveTime": "20240212",
  "ingredients": [
    {
      "name": "VARENICLINE TARTRATE",
      "code": "82269ASB48"
    },
    {
      "name": "SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE",
      "code": "70WT22SF4B"
    },
    {
      "name": "SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS",
      "code": "KH7I04HPUU"
    },
    {
      "name": "SODIUM CHLORIDE",
      "code": "451W47IQ8X"
    },
    {
      "name": "SODIUM HYDROXIDE",
      "code": "55X04QC32I"
    },
    {
      "name": "HYDROCHLORIC ACID",
      "code": "QTT17582CB"
    },
    {
      "name": "WATER",
      "code": "059QF0KO0R"
    }
  ],
  "indications": "1 INDICATIONS AND USAGE TYRVAYA ( varenicline solution ) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease. TYRVAYA ( varenicline solution ) nasal spray is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease. ( 1 )",
  "contraindications": "4 CONTRAINDICATIONS None None.",
  "warningsAndPrecautions": null,
  "adverseReactions": "6 ADVERSE REACTIONS The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site ( nose ) irritation. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Oyster Point Pharma at 1-877-EYE-0123 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In three clinical studies of dry eye disease conducted with varenicline solution nasal spray, 349 patients received at least 1 dose of TYRVAYA. The majority of patients had 31 days of treatment exposure, with a maximum exposure of 105 days. The most common adverse reactions reported in 82% of TYRVAYA treated patients was sneezing. Other common adverse reactions that were reported in >5% of patients include cough ( 16% ) , throat irritation ( 13% ) , and instillation-site ( nose ) irritation ( 8% ) ."
}